Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

By J. Vredenburgh, A. Desjardins, J. Herndon, J. Dowell, D. Reardon, J. Quinn, Jeremy N. Rich, S. Sathornsumetee, S. Gururangan, Melissa Wagner and 3 more. Clinical Cancer Research, 2007

1,087 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0f229625dde453ecb2fff76cc86f168defc39c74

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Malignant astrocytic glioma: genetics, biology, and paths to treatment. (2007, background): “…testing that aim to target VEGF/VEGFR signaling pathways: (1) monoclonal antibodies directed against VEGF or its receptor(s) (Winkler et al. 2004; Vredenburgh et al. 2007), (2) small molecule inhibitors of VEGFR-2 tyrosine kinase activity (Batchelor et al. 2007), and (3) soluble decoy receptors…”
The Hypoxic Microenvironment Maintains Glioblastoma Stem Cells and Promotes Reprogramming towards a Cancer Stem Cell Phenotype (2009, background): “Targeted therapies have largely failed in clinical trial with the notable exception of bevacizumab (Avastin), a neutralizing antibody against vascular endothelial growth factor (VEGF).(3,4) Despite substantial research efforts, the mechanisms underlying the overwhelming lethality of glioblastomas re”
Angiogenesis in brain tumours (2007, background): “Data consistent with the preclinical findings are beginning to emerge from the clinical settin”
Making a tumour's bed: glioblastoma stem cells and the vascular niche (2007, background): “, and that these tumours are sensitive to treatment with the anti-VEGF antibody bevacizuma”
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma (2008, background): “For example, if rapamycin in these patients is sequestered in red cells due to enhanced tumor vascularity, antiangiogenic agents such as bevacizumab (already known to have activity in glioblastoma) [44] may prevent sequestration and allow more efficient drug delivery.”
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (2007, background): “Because the majority of patients fail to respond to temozolomide in the up-front or recurrent disease setting, clearly, new regimens are needed for the more formidable recurrent GBM.”
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma (2011, result): “This is in full agreement with reported clinical data (4, 17, 18).”